Abeona Therapeutics (ABEO) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings or view top-rated stocks.

2 brokerages have issued 1 year price targets for Abeona Therapeutics' shares. Their ABEO share price forecasts range from $40.00 to $40.00. On average, they anticipate the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 1,108.5% from the stock's current price.
View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts.

Abeona Therapeutics' stock was trading at $3.08 at the beginning of 2023. Since then, ABEO shares have increased by 7.5% and is now trading at $3.31.
View the best growth stocks for 2023 here.

Abeona Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 366,600 shares, a decrease of 28.4% from the April 30th total of 512,300 shares. Based on an average daily trading volume, of 142,400 shares, the days-to-cover ratio is currently 2.6 days. Approximately 2.0% of the shares of the company are short sold.
View Abeona Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ABEO earnings forecast.

Abeona Therapeutics Inc (NASDAQ:ABEO) released its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($4.00).

Shares of Abeona Therapeutics reverse split on the morning of Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Abeona Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.97%), Knott David M Jr (0.90%), ExodusPoint Capital Management LP (0.68%), State Street Corp (0.23%), Renaissance Technologies LLC (0.21%) and Charles Schwab Investment Management Inc. (0.10%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc and Todd Wider.
View institutional ownership trends.

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABEO stock can currently be purchased for approximately $3.31.

Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $62.16 million and generates $1.07 million in revenue each year.

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101.